TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update

TScan Therapeutics, Inc. (NASDAQ:TCRX) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 1,800,000 shares, an increase of 31.4% from the August 31st total of 1,370,000 shares. Approximately 4.3% of the company’s shares are sold short. Based on an average trading volume of 360,200 shares, the days-to-cover ratio is currently 5.0 days.

TScan Therapeutics Stock Up 1.4 %

Shares of NASDAQ TCRX traded up $0.07 during midday trading on Friday, hitting $5.04. 170,490 shares of the stock traded hands, compared to its average volume of 248,888. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.77 and a current ratio of 7.77. TScan Therapeutics has a one year low of $2.43 and a one year high of $9.69. The business has a 50 day moving average price of $5.97 and a two-hundred day moving average price of $7.01. The company has a market cap of $266.97 million, a PE ratio of -3.88 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. The business had revenue of $0.54 million during the quarter, compared to analyst estimates of $1.55 million. On average, equities analysts predict that TScan Therapeutics will post -1.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TCRX. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a report on Monday, August 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a research report on Monday, August 12th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $12.00.

Insider Buying and Selling at TScan Therapeutics

In related news, Director Barbara Klencke bought 5,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $5.69 per share, with a total value of $28,450.00. Following the acquisition, the director now owns 35,000 shares of the company’s stock, valued at $199,150. The purchase was disclosed in a filing with the SEC, which is available through this link. In other news, Director Barbara Klencke bought 5,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was acquired at an average price of $5.69 per share, with a total value of $28,450.00. Following the transaction, the director now owns 35,000 shares of the company’s stock, valued at approximately $199,150. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Zoran Zdraveski sold 164,686 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the transaction, the insider now owns 4,716 shares in the company, valued at approximately $27,258.48. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 15,000 shares of company stock worth $82,550. 2.76% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TCRX. Vanguard Group Inc. increased its holdings in TScan Therapeutics by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after purchasing an additional 20,000 shares in the last quarter. Great Point Partners LLC purchased a new position in shares of TScan Therapeutics during the second quarter valued at approximately $5,504,000. Marshall Wace LLP grew its holdings in TScan Therapeutics by 60.8% during the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock worth $1,799,000 after buying an additional 116,316 shares in the last quarter. Tocqueville Asset Management L.P. purchased a new stake in TScan Therapeutics in the 1st quarter valued at $1,685,000. Finally, Bank of Montreal Can purchased a new stake in TScan Therapeutics in the 2nd quarter valued at $749,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.